This filing confirms RA Capital as a major pre-IPO holder with board representation. Monitor for an S-1 registration statement or IPO pricing announcement, as the conversion mechanics are tied to the IPO closing. The filing itself is routine and does not alter the current trading outlook.
Price Chart
Executive Summary
RA Capital Management and affiliated entities filed Form 3 initial statements of beneficial ownership for Hemab Therapeutics (COAG), disclosing aggregate holdings of approximately 4.6 million shares of Common Stock on an as-converted basis from Series A, B, and C Preferred Stock. This is a routine initial ownership filing by a significant pre-IPO investor, confirming RA Capital's substantial stake ahead of a potential IPO.
Key Facts
- RA Capital Management, L.P. and affiliated funds (RA Capital Healthcare Fund LP, Nexus Fund II, Nexus Fund IV) filed Form 3 initial ownership statements for Hemab Therapeutics.
- RA Capital Healthcare Fund LP holds 1,422,960 shares of Common Stock (on as-converted basis from Series A Preferred).
- RA Capital Nexus Fund II, L.P. holds 609,840 shares (Series A Preferred).
- RA Capital Nexus Fund IV, L.P. holds 931,502 shares (Series B Preferred) and 1,253,384 shares (Series C Preferred).
- Peter Kolchinsky and Rajeev M. Shah, managing members of RA Capital, are also reporting owners.
- Dr. Laura Tadvalkar, a Managing Director of RA Capital, serves on Hemab's board of directors.
- Preferred shares convert to Common Stock on a 22-for-1 basis immediately prior to the closing of the Issuer's initial public offering.
Financial Impact
RA Capital's aggregate beneficial ownership totals approximately 4,617,596 shares of Common Stock on an as-converted basis, representing a significant pre-IPO stake. No dollar amounts disclosed.
Risk Factors
- No material financial or operational data disclosed; filing is purely administrative.
- No indication of insider buying or selling activity beyond initial ownership reporting.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001231919-26-000435 |
| Document: 0001231919-26-000435-index.html | 0001231919-26-000435 |
| Document: 0001231919-26-000435.txt | 0001231919-26-000435 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access